Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018 Denosumab
and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources
WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that A...
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
...cial performance in 2009 and are focused on making denosumab
a success," said Kevin Sharer, chairman and chief ...y driven by lower
clinical trial costs for denosumab
and Vectibix registrational
studies, parti... of its pivotal, Phase 3, head-to-head study where denosumab
demonstrated superiority versus Zometa((R)) (zoled...
Amgen Highlights Data to Be Presented at ASCO
...7 (Saturday, May 30, 2009, 4:15pm-4:30pm)
Researchers will present data from the denosumab
oncology development program, including an oral pr...ion of final Phase 2 data looking at the effect of denosumab
on the treatment of giant cell tumor (GCT) of the ...
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
...e have made progress on our plans to commercialize denosumab
for PMO. Also, we are looking forward to reviewing important data on pipeline products including denosumab
in certain oncology indications and Vectibix in co...arily driven by lower clinical trial costs for the denosumab
registrational studies due to completion of enroll...
Latest Osteoporosis Research Translated for Health Professionals to Use in Clinical Setting
... such as: Secondary Causes of Bone Loss; Bone Quality: New Imaging to Refine Fracture Risk and Improve Therapy; and Emerging Pharmaceutical Therapies: denosumab
and New EAAs
EVENT: 8th International Symposium on Osteoporosis: Translating Clinical Research Into Practice
WHEN: April 1-5, 2009
24th Annual EAU Congress highlights many new developments
Dr. Smith from Boston (U.S.) is keen on presenting the exciting results of his trial (A randomized, double-blind, placebo-controlled trial of denosumab
in men receiving androgen deprivation therapy for non-metastatic prostate cancer) from 10:25 to 10:55 hours as part of the 'The best EAU papers' sessi...
New Drug May Strengthen Women's Bones
... In study, denosumab
outperformed a standard ,,osteoporosis therapy
MONDAY, Oct. 27 (HealthDay News) -- The drug denosumab
can boost bone mass in postmenopausal women, accor... 64, with low bone mass for more than one year.
inhibits the activation of bone-resorbing cells ca...
Denosumab Reduces Bone Erosion
...ented at EULAR 2007, the Annual
Treatment with denosumab
60 mg and 180 mg (with background methotrexate) re...trial, six and 12 months to assess the capacity of denosumab
to reduce progression of RA associated bone erosio...al of denosumab, revealing that patients receiving denosumab
experienced a reduced progression of erosions comp...
Doctors Hopeful for Elizabeth Edwards
...is may include drugs that block estrogen, if the tumor is fueled by that hormone, or chemotherapy. Looking to the future, a monoclonal antibody called denosumab
is currently in clinical trials for use against both bone metastasis and osteoporosis, say scientists.
While the treatments now available can onl...
Bone Density Can Be Beefed Up With Twice-a-year shots
...cording to a study, Amgen Inc.'s experimental drug denosumab
taken twice a year can rejuvenate the density of b...
It was observed that after a year of treatment, denosumab
strengthened the bone density in the lumbar portio...t, those women who got a 60 milligram injection of denosumab
every six months, showed the best result. Till dat...
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab
for postmenopausal osteoporosi...
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. Th...
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
... Advisory Committee to Review denosumab
THOUSAND OAKS, Calif., June 22 /PRNewswi.... We look forward to discussing the data from our denosumab
trials in these settings with the members of the C...ts, the incidence and types of adverse events with denosumab
were similar to placebo. The most common adverse e...
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
...lso submitted an application in Canada for these indications.
In the European Union, the Company has submitted an application for the approval of denosumab
for treatment of PMO in women, and treatment of bone loss associated with hormone ablation therapy in patients with breast and prostate cancer.
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
...s pipeline -- including the
experimental bone drug denosumab
-- growing in-line products and continuing
blockbuster status: Sensipar(R) (cinacalcet), denosumab
for cancer-related indications."
Roger M. Perlmu...
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
... and chief executive officer. "We are now focused on
plans to commercialize denosumab
in post-menopausal osteoporosis. We're
excited about the opportunity to bri...r our emerging pipeline were offset by lower clinical trial costs for our denosumab
registrational studies due to completion of enrollment and the benefit de...
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
... SAN ANTONIO, Dec. 15 /PRNewswire/ -- denosumab
is a new drug being
studied to prevent fractures i...therapy. Results of a phase 3 clinical trial using denosumab
Friday evening at the San Antonio B...llis, MD, from the Seattle Cancer Care Alliance.
is a highly specific antibody that interrupts the ...